FibroGen received approval from the China State Administration for Market Regulation to sell FibroGen International (Hong Kong) Ltd. to AstraZeneca. The transaction is expected to close in Q3 2025 with a total consideration of approximately $210 million.

AstraZeneca has acquired FibroGen's Chinese subsidiary for $160 million, strengthening its position in the Chinese market and enabling FibroGen to focus on its pipeline development in the US.

The global liver fibrosis market is expected to grow from $17.25 billion in 2021 to $43.98 billion by 2030, driven by the increasing prevalence of liver disorders, adaptation of unhealthy lifestyles, and the rising geriatric population. The North American region dominates the market due to high healthcare expenditure and the presence of major pla...

The Catalyst Accelerator Ogden, in collaboration with the Department of the Air Force Digital Transformation Office, has selected 11 innovative small businesses to address the Air Force's digital modernization challenges through cutting-edge technologies in areas such as AI/ML, data fusion, automation, and cybersecurity.

FibroGen Inc (NASDAQ:FGEN) shares are moving higher in Monday’s after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) for FG-3165. The company also announced a new clinical trial supply agreement with Regeneron. What Happened: After the market close on Monday, FibroGen said the FDA cleared its IND of...